Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis

Authors: Thaís Brilhante Pontes, Elizabeth Suchi Chen, Carolina Oliveira Gigek, Danielle Queiroz Calcagno, Fernanda Wisnieski, Mariana Ferreira Leal, Samia Demachki, Paulo Pimentel Assumpção, Ricardo Artigiani, Laércio Gomes Lourenço, Rommel Rodriguez Burbano, Marília Arruda Cardoso Smith

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Aberrant methylation has been reported in several neoplasias, including gastric cancer. The methyl-CpG-binding domain (MBD) family proteins have been implicated in the chromatin remodeling process, leading to the modulation of gene expression. To evaluate the role of MBD2 and MBD3 in gastric carcinogenesis and the possible association with clinicopathological characteristics, we assessed the mRNA levels and promoter methylation patterns in gastric tissues. In this study, MBD2 and MBD3 mRNA levels were determined by RT-qPCR in 28 neoplastic and adjacent nonneoplastic and 27 gastritis and non-gastritis samples. The promoter methylation status was determined by bisulfite sequencing, and we found reduced MBD2 and MBD3 levels in the neoplastic samples compared with the other groups. Moreover, a strong correlation between the MBD2 and MBD3 expression levels was observed in each set of paired samples. Our data also showed that the neoplastic tissues exhibited higher MBD2 promoter methylation than the other groups. Interestingly, the non-gastritis group was the only one with positive methylation in the MBD3 promoter region. Furthermore, a weak correlation between gene expression and methylation was observed. Therefore, our data suggest that DNA methylation plays a minor role in the regulation of MBD2 and MBD3 expression, and the presence of methylation at CpGs that interact with transcription factor complexes might also be involved in the modulation of these genes. Moreover, reduced mRNA expression of MBD2 and MBD3 is implicated in gastric carcinogenesis, and thus, further investigations about these genes should be conducted for a better understanding of the role of abnormal methylation involved in this neoplasia.
Literature
1.
Jemal A et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S17–25. e1-3.PubMed
2.
Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266(2):99–115.PubMedCrossRef
3.
4.
5.
6.
Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem. 2002;277(38):35434–9.PubMedCrossRef
7.
Zhang Y et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999;13(15):1924–35.PubMedCentralPubMedCrossRef
8.
Le Guezennec X et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 2006;26(3):843–51.PubMedCentralPubMedCrossRef
9.
10.
Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat Rev Cancer. 2011;11(8):588–96.PubMedCrossRef
11.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Immunol Scand. 1965;64:31–49.
12.
13.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.
14.
15.
16.
Messeguer X et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18(2):333–4.PubMedCrossRef
17.
Lopez-Serra L et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene. 2008;27(25):3556–66.PubMedCrossRef
18.
Parry L, Clarke AR. The roles of the methyl-CpG binding proteins in cancer. Cancer Gene Ther. 2011;2(6):618–30.CrossRef
19.
Sansom OJ, Maddison K, Clarke AR. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol. 2007;4(5):305–15.PubMedCrossRef
20.
Amir RE et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–8.PubMedCrossRef
21.
22.
23.
Kanai Y et al. Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun. 1999;264(3):962–6.PubMedCrossRef
24.
Maekita T et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12(3 Pt 1):989–95.PubMedCrossRef
25.
Lima EM et al. Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res. 2008;41(6):539–43.PubMedCrossRef
26.
Gigek CO et al. Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma. Growth Horm IGF Res. 2010;20(3):234–8.PubMedCrossRef
27.
Leal MF et al. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from northern Brazil. World J Gastroenterol. 2007;13(18):2568–74.PubMed
28.
Gigek CO et al. hTERT methylation and expression in gastric cancer. Biomarkers. 2009;14(8):630–6.PubMedCrossRef
29.
Angrisano T et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 2006;34(1):364–72.PubMedCentralPubMedCrossRef
30.
Chatagnon A et al. Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis. 2009;30(1):28–34.PubMedCrossRef
31.
32.
Kaji K et al. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat Cell Biol. 2006;8(3):285–92.PubMedCrossRef
33.
Aguilera C et al. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature. 2011;469(7329):231–5.PubMedCrossRef
34.
Sato M et al. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene. 2002;21(31):4822–9.PubMedCrossRef
35.
Liu C et al. Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knock-down by stable RNA interference. BMC Cancer. 2008;8:121.PubMedCentralPubMedCrossRef
36.
Luo G et al. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol Ther. 2009;8(7):594–8.PubMedCrossRef
37.
Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 1998;18(11):6538–47.PubMedCentralPubMed
38.
Gunther K et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 2013;41(5):3010–21.PubMedCentralPubMedCrossRef
39.
Brackertz M et al. Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3. J Biol Chem. 2002;277(43):40958–66.PubMedCrossRef
40.
Tatematsu KI, Yamazaki T, Ishikawa F. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells. 2000;5(8):677–88.PubMedCrossRef
41.
Watabe Y et al. Aryl hydrocarbon receptor functions as a potent coactivator of E2F1-dependent trascription activity. Biol Pharm Bull. 2010;33(3):389–97.PubMedCrossRef
42.
Xanthoulis A, Tiniakos DG. E2F transcription factors and digestive system malignancies: how much do we know? World J Gastroenterol. 2013;19(21):3189–98.PubMedCentralPubMedCrossRef
43.
Consortium EP et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.CrossRef
44.
Chen YJ et al. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol. 2012;18(29):3849–61.PubMedCentralPubMedCrossRef
45.
Yuan K et al. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Am J Gastroenterol. 2013;145(4):853–64. e9.
46.
Zhang X et al. MicroRNA-373 is upregulated and targets TNFAIP1 in human gastric cancer, contributing to tumorigenesis. Oncol Lett. 2013;6(5):1427–34.PubMedCentralPubMed
47.
Liu K et al. Increased expression of MicroRNA-221 in gastric cancer and its clinical significance. J Int Med Res. 2012;40(2):467–74.PubMedCrossRef
Metadata
Title
Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis
Authors
Thaís Brilhante Pontes
Elizabeth Suchi Chen
Carolina Oliveira Gigek
Danielle Queiroz Calcagno
Fernanda Wisnieski
Mariana Ferreira Leal
Samia Demachki
Paulo Pimentel Assumpção
Ricardo Artigiani
Laércio Gomes Lourenço
Rommel Rodriguez Burbano
Marília Arruda Cardoso Smith
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1455-y

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Review

A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer

Research Article

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer

Research Article

The prognostic value of Smad4 mRNA in patients with prostate cancer

Research Article

RETRACTED ARTICLE: Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1

Research Article

Truncation of inhibitor of growth family protein 5 effectively induces senescence, but not apoptosis in human tongue squamous cell carcinoma cell line

Review

MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits